Free Trial

Pasithea Therapeutics (KTTA) Competitors

Pasithea Therapeutics logo
$0.71 -0.01 (-0.78%)
As of 09:40 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

KTTA vs. GBIO, FGEN, FNCH, DARE, SLGL, MIRA, NAII, BCTX, RLMD, and DRRX

Should you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Generation Bio (GBIO), FibroGen (FGEN), Finch Therapeutics Group (FNCH), Dare Bioscience (DARE), Sol-Gel Technologies (SLGL), MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Briacell Therap (BCTX), Relmada Therapeutics (RLMD), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry.

Pasithea Therapeutics vs. Its Competitors

Generation Bio (NASDAQ:GBIO) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Generation Bio presently has a consensus price target of $7.33, suggesting a potential upside of 1,965.73%. Given Generation Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Generation Bio is more favorable than Pasithea Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Generation Bio
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Pasithea Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Pasithea Therapeutics has lower revenue, but higher earnings than Generation Bio. Generation Bio is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Generation Bio$19.89M1.20-$131.67M-$1.08-0.33
Pasithea TherapeuticsN/AN/A-$13.90M-$10.60-0.07

Generation Bio has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500.

In the previous week, Generation Bio had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Generation Bio and 0 mentions for Pasithea Therapeutics. Generation Bio's average media sentiment score of 0.36 beat Pasithea Therapeutics' score of 0.00 indicating that Generation Bio is being referred to more favorably in the media.

Company Overall Sentiment
Generation Bio Neutral
Pasithea Therapeutics Neutral

Pasithea Therapeutics has a net margin of 0.00% compared to Generation Bio's net margin of -292.92%. Generation Bio's return on equity of -75.84% beat Pasithea Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Generation Bio-292.92% -75.84% -30.40%
Pasithea Therapeutics N/A -88.14%-81.21%

95.2% of Generation Bio shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 21.1% of Generation Bio shares are held by insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Generation Bio beats Pasithea Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KTTA vs. The Competition

MetricPasithea TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.29M$2.88B$5.50B$8.94B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-0.0720.8026.9720.11
Price / SalesN/A287.03426.02119.76
Price / CashN/A41.1936.8257.86
Price / Book0.077.487.985.56
Net Income-$13.90M-$55.04M$3.16B$248.40M
7 Day Performance-4.92%2.44%2.36%4.67%
1 Month Performance-21.00%1.90%2.15%6.64%
1 Year Performance-87.23%4.35%33.78%21.31%

Pasithea Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KTTA
Pasithea Therapeutics
0.9796 of 5 stars
$0.71
-0.8%
N/A-86.0%$5.29MN/A-0.073Gap Up
GBIO
Generation Bio
3.4307 of 5 stars
$0.32
0.0%
$7.33
+2,191.7%
-85.0%$21.46M$19.89M-0.30150News Coverage
High Trading Volume
FGEN
FibroGen
4.6939 of 5 stars
$5.27
-0.6%
$250.00
+4,643.8%
-72.2%$21.42M$29.62M-2.11570Positive News
FNCH
Finch Therapeutics Group
1.054 of 5 stars
$13.20
flat
N/A+870.1%$21.20M$110K-1.50190
DARE
Dare Bioscience
1.5722 of 5 stars
$2.37
-0.8%
$12.00
+406.3%
-22.3%$21.15M$10K-13.9430
SLGL
Sol-Gel Technologies
2.6268 of 5 stars
$7.40
-0.1%
$40.00
+440.9%
-13.5%$20.61M$11.54M-1.5750
MIRA
MIRA Pharmaceuticals
2.6545 of 5 stars
$1.21
flat
$14.00
+1,057.0%
+106.3%$20.47MN/A-2.372
NAII
Natural Alternatives International
0.873 of 5 stars
$3.26
-0.6%
N/A-40.1%$20.27M$113.80M-2.35290Positive News
Gap Up
BCTX
Briacell Therap
2.3313 of 5 stars
$2.86
-2.7%
$32.00
+1,018.9%
-81.7%$19.92MN/A-0.348News Coverage
RLMD
Relmada Therapeutics
4.5932 of 5 stars
$0.62
+2.6%
$5.00
+711.6%
-80.9%$19.92MN/A-0.2510
DRRX
DURECT
0.5376 of 5 stars
$0.64
+0.8%
N/A-50.5%$19.72M$2.03M-4.2780Gap Down

Related Companies and Tools


This page (NASDAQ:KTTA) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners